RecruitingAlzheimer Disease
Cognitive Neurology Unit Clinical Registry
Eligible age
50–95 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease
Sponsor: Beth Israel Deaconess Medical Center
You may qualify if…
- ✓ o Patient meets clinical criteria for mild cognitive impairment or early dementia from Alzheimer's disease
- ✓ Patient has evidence of cognitive impairment on neuropsychological testing
- ✓ Patient has not progressed to the moderate stage of dementia based on neuropsychological testing or clinical judgement
- ✓ Amyloid PET imaging and/or CSF analysis consistent with Alzheimer's disease
- ✓ Amyloid PET imaging positive
- ✓ CSF p-Tau/Abeta42 ration \>0.023 and ABeta42 \< 1027\*\*
- ✓ 3T MRI in past 6 months
- ✓ Patient has a care partner
You may not qualify if…
- ✕ o Recent stroke or suspected TIA in the past year
- ✕ Pregnancy
- ✕ Active autoimmune or immunological disease
- ✕ Systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives
- ✕ Bleeding disorder with Plts \< 50,000 or INR \> 1.5
- ✕ On warfarin, heparin, or DOAC
- ✕ On dual antiplatelet therapy
- ✕ Non Alzheimer disease cause of dementia/MCI
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT05925621 · last updated 2026-04-13